Alkermes plc Watch

EX-10.2B

from 10-Q 3 pages 2018 Plan Award Certificate - Non-Employee Director Restricted Stock Unit (Time-Vesting) Alkermes plc Connaught House 1 Burlington Road Dublin 4, Ireland Name: Participant Name Address: Participant Address Grant Id: Grant Id Plan: Plan Id Id: Grantee Id

12/34/56

EX-10.2A

from 10-Q 3 pages 2018 Plan Award Certificate - Non-Employee Director Non-Qualified Stock Option Alkermes plc Connaught House 1 Burlington Road Dublin 4, Ireland Name: Participant Name Address: Participant Address Grant Id: Grant Id Plan: Plan Id Id: Optionee Id

12/34/56

EX-10.1

from 10-Q 4 pages Fifth Amendment to License and Collaboration Agreement

12/34/56

EX-10.1

from 8-K 15 pages Alkermes plc 2018 Stock Option and Incentive Plan, as Amended

12/34/56

EX-10.5A

from 10-K 13 pages Portions of This Exhibit (Indicated by “[**]”) Have Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K. Schedules and Similar Attachments to This Exhibit Have Been Omitted Pursuant to Item 601(a)(5) of Regulation S-K. Third Amendment to Development and License Agreement

12/34/56

EX-10.25N

from 10-K 4 pages 2018 Plan Award Certificate – Restricted Stock Unit (Performance-Vesting)_(rev. 2024) Alkermes plc Connaught House 1 Burlington Road Dublin 4, Ireland Name: Participant Name Address: Participant Address Grant Id: Grant Id Plan: Plan Id Id: Grantee Id

12/34/56

EX-10.25M

from 10-K 4 pages 2018 Plan Award Certificate –Performance-Vesting Restricted Stock Unit Award (Reporting Officer)_(rev. 2024) Alkermes plc Connaught House 1 Burlington Road Dublin 4, Ireland Name: Participant Name Address: Participant Address Grant Id: Grant Id Plan: Plan Id Id: Optionee Id

12/34/56

EX-10.13A

from 10-K 4 pages Amendment to Employee Matters Agreement

12/34/56

EX-10.16

from 10-K 72 pages Portions of This Exhibit (Indicated by “[**]”) Have Been Omitted Pursuant to Item 601(b) of Regulation S-K. Schedules and Similar Attachments to This Exhibit Have Been Omitted Pursuant to Item 601(a)(5) of Regulation S-K. Asset Purchase Agreement Dated as of 13 December 2023 Among Alkermes Pharma Ireland Limited -And- Novo Nordisk Production Ireland Limited -And- Novo Nordisk a/S

12/34/56

EX-10.5

from 10-K 30 pages Portions of This Exhibit (Indicated by “[**]”) Have Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K. Schedules and Similar Attachments to This Exhibit Have Been Omitted Pursuant to Item 601(a)(5) of Regulation S-K. Development and License Agreement

12/34/56

EX-10.4

from 8-K 26 pages Transition Services Agreement by and Between Mural Oncology, Inc. and Alkermes, Inc. Dated as of November 13, 2023 Transition Services Agreement

12/34/56

EX-10.3

from 8-K 27 pages Transition Services Agreement by and Between Alkermes, Inc. and Mural Oncology, Inc. Dated as of November 13, 2023 Transition Services Agreement

12/34/56

EX-10.2

from 8-K 29 pages Employee Matters Agreement by and Between Alkermes plc and Mural Oncology PLC Dated as of November 13, 2023 1 Employee Matters Agreement

12/34/56

EX-10.1

from 8-K 37 pages Tax Matters Agreement by and Between Alkermes plc and Mural Oncology PLC Dated as of November 13, 2023 Tax Matters Agreement

12/34/56

EX-10.3

from 10-Q 19 pages Portions of This Exhibit (Indicated by “[**]”) Have Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K

12/34/56

EX-10.2

from 10-Q 32 pages Portions of This Exhibit (Indicated by “[**]”) Have Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K

12/34/56

EX-10.1

from 10-Q 22 pages Portions of This Exhibit (Indicated by Asterisks) Have Been Omitted Pursuant to Item 601(b)(10)(iv) of Regulation S-K. Confidential Settlement and License Agreement

12/34/56

EX-10.1

from 8-K 15 pages Alkermes plc 2018 Stock Option and Incentive Plan, as Amended

12/34/56

EX-10.2

from 10-Q 5 pages “Agreement Amendment No. 2”

12/34/56

EX-10.1

from 10-Q 45 pages License Agreement by and Among Elan Pharmaceutical Research Corp., D/B/a Nanosystems and Elan Pharma International Limited and Janssen Pharmaceutica N.V. March 31, 1999 This Document Is the Confidential Information of Both Parties Hereto. It Should Be Distributed on a Need-To-Know Basis and Kept in Secure Area

12/34/56